ArticleNature2019
Human blood vessel organoids as a model of diabetic vasculopathy.
Open access · greenAbstract read
In one paragraph
Article in Nature, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 451 papers.
0numbers the graph read from it
0cells of the map it votes in
451citing papers in PubMed
39.6field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
451 citing papers in PubMed, 762 citations in OpenAlex.
- A double-layer scaffold composed of 3D bioprinted layer of granulocyte-colony stimulating factor and electrospun nanofibers of abietic acid for full thickness skin repair.International journal of pharmaceutics: X · 2026Article
- A viscoelastic suspension culture strategy modulating fusion and development in blood vessel organoids.Bioactive materials · 2026Article
- Modeling Moyamoya disease using patient-derived induced pluripotent stem cells and organoids.Molecular biology reports · 2026Review
- Nonexpansive biodegradable matrix promotes blood vessel organoid development for neurovascular repair and functional recovery in ischaemic stroke.Nature biomedical engineering · 2026Article
- Vascularized human skin assembloids model compartmental skin organization and immune responsiveness in vitro.Experimental & molecular medicine · 2026Article
- Immunoids: Building immunocompetent organoids from human pluripotent stem cells.Cell stem cell · 2026Review
- Bioelectric signals promote diabetic bone regeneration through Piezo1-mediated activation of the efferocytic immune microenvironment.Bioactive materials · 2026Article
- Brazilin attenuates methylglyoxal‑induced endothelial injury by enhancing eIF5A hypusination and inhibiting the AMPK/mTOR‑mediated autophagy/apoptosis axisInternational journal of molecular medicine · 2026Article
- Pharmacokinetic and Pharmacodynamic Drug-Drug Interactions Between Cofrogliptin and Metformin in Healthy Subjects: A Single-Center, Single-Arm, Phase I Study in China.Clinical pharmacology in drug development · 2026Article
- Differentiation of arterioles and capillaries in human blood vessel organoids with decellularized splenic matrix.Bioactive materials · 2026Article
- 3D bioprinted human vascular organoid sheets promote functional ischemic repair and exhibit adaptive in vivo remodeling.BMC medicine · 2026Article
- Using Brain Organoids to Explore Human Neurobiology.Cellular and molecular neurobiology · 2026Review
- Transcriptional dynamics of the murine heart during perinatal development at single-cell resolution.Biology open · 2026Article
- Stepwise Evolution of Immunodeficient Mouse Models: Focus on NCG Strains and Their Applications in Humanized Immune System Research.Vaccines · 2026Review
- Self-organization of vascularized muscle from bovine embryonic stem cells.Nature communications · 2026Article
- Induced pluripotent stem cells from discovery to translation.Nature medicine · 2026Review
- Vascularized Brain Organoids: Advances in Engineering Human Neurovascular Models.International journal of stem cells · 2026Review
- Hypertensive mt. tRNARedox biology · 2026Article
- Advances in vascularized organoids.Chinese medical journal · 2026Review
- Enabling Technologies in Vascular Biology: Microphysiological Systems, Organoids, and Beyond.Arteriosclerosis, thrombosis, and vascular biology · 2026Review
391 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
Authors and funding
20 authors at 6 institutions in 3 countries.
Reiner A WimmerInstitute of Molecular Biotechnology of the Austrian Academy of Sciences (IMBA), Vienna, Austria. reiner.wimmer@imba.oeaw.ac.at.
Alexandra LeopoldiInstitute of Molecular Biotechnology of the Austrian Academy of Sciences (IMBA), Vienna, Austria.
Martin AichingerInstitute of Molecular Pathology (IMP), Vienna, Austria.
Nikolaus WickClinical Department of Pathology, Medical University Vienna, Vienna, Austria.
Brigitte HantuschClinical Department of Pathology, Medical University Vienna, Vienna, Austria.
Maria NovatchkovaInstitute of Molecular Biotechnology of the Austrian Academy of Sciences (IMBA), Vienna, Austria.
Jasmin TaubenschmidInstitute of Molecular Biotechnology of the Austrian Academy of Sciences (IMBA), Vienna, Austria.
Monika HämmerleClinical Department of Pathology, Medical University Vienna, Vienna, Austria.
Christopher EskInstitute of Molecular Biotechnology of the Austrian Academy of Sciences (IMBA), Vienna, Austria.
Joshua A BagleyInstitute of Molecular Biotechnology of the Austrian Academy of Sciences (IMBA), Vienna, Austria.
Dominik LindenhoferInstitute of Molecular Biotechnology of the Austrian Academy of Sciences (IMBA), Vienna, Austria.
Guibin ChenCenter for Molecular Medicine, National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH), Bethesda, MD, USA.
Manfred BoehmCenter for Molecular Medicine, National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH), Bethesda, MD, USA.
Chukwuma A AguInstitute of Molecular Biotechnology of the Austrian Academy of Sciences (IMBA), Vienna, Austria.
Fengtang YangWellcome Trust Sanger Institute, Hinxton, UK.
Beiyuan FuWellcome Trust Sanger Institute, Hinxton, UK.
Johannes ZuberInstitute of Molecular Pathology (IMP), Vienna, Austria.
Juergen A KnoblichInstitute of Molecular Biotechnology of the Austrian Academy of Sciences (IMBA), Vienna, Austria.
Dontscho KerjaschkiClinical Department of Pathology, Medical University Vienna, Vienna, Austria.
Josef M PenningerInstitute of Molecular Biotechnology of the Austrian Academy of Sciences (IMBA), Vienna, Austria. josef.penninger@imba.oeaw.ac.at.
Institute of Molecular Biotechnology · ATAustrian Academy of Sciences · ATMedical University of Vienna · ATNational Heart Lung and Blood Institute · USResearch Institute of Molecular Pathology · ATWellcome Sanger Institute · GB
Funding
Vascular remodeling in patients with rare genetic disordersZIAHL006077 · NHLBI · NATIONAL HEART, LUNG, AND BLOOD INSTITUTE · PI BOEHM, MANFRED · 2010 to 2025
$22.9MiPS-technology and patient specific disease modelsZIAHL006079 · NHLBI · NATIONAL HEART, LUNG, AND BLOOD INSTITUTE · PI BOEHM, MANFRED · 2010 to 2025
$14.4MAustrian Science Fund FWF Z 271European Research Council 341036
Abstract
The increasing prevalence of diabetes has resulted in a global epidemic
Indexed as
Models, BiologicalAdaptor Proteins, Signal TransducingAmyloid Precursor Protein SecretasesAnimalsArteriesArteriolesBasement MembraneBlood VesselsCalcium-Binding ProteinsDiabetic AngiopathiesEndothelial CellsHumansHyperglycemiaInflammation MediatorsIntercellular Signaling Peptides and ProteinsIn Vitro TechniquesAdaptor Proteins, Signal TransducingAmyloid Precursor Protein SecretasesCalcium-Binding ProteinsDLL4 protein, humanInflammation MediatorsIntercellular Signaling Peptides and ProteinsNOTCH3 protein, humanReceptor, Notch3
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.